Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.41 |
| ▸ | TLR2 | O60603 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21287666 | 0.93 | GLP1R (0.41) | GLP1RTLR2 | |
| SCHEMBL20800942 | 0.90 | GLP1R (0.42) | GLP1RTLR2 | |
| SCHEMBL20375511 | 0.89 | GLP1R (0.41) | GLP1RTLR2 | |
| SCHEMBL20375520 | 0.88 | GLP1R (0.40) | GLP1RTLR2 | |
| SCHEMBL18715475 | 0.84 | GLP1R (0.48) | GLP1RTLR2 | |
| SCHEMBL24697314 | 0.84 | GLP1R (0.40) | GLP1R | |
| SCHEMBL21287290 | 0.83 | GLP1R (0.42) | GLP1RTLR2 | |
| SCHEMBL24697694 | 0.81 | GLP1R (0.41) | GLP1RTLR2 | |
| SCHEMBL21287433 | 0.81 | GLP1R (0.46) | GLP1RTLR2 | |
| SCHEMBL21393232 | 0.80 | GLP1R (0.40) | GLP1RTLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11492624-B2 | RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1 | Arrowheads Pharmaceuticals, Inc. (US) | 2022-11-08 | — | — | US | disclosed |
| US-10995335-B2 | RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2021-05-04 | — | — | US | disclosed |
| US-20200283777-A1 | RNAi Agents And Compositions for Inhibiting Expression of Asiaglycoprotein Receptor 1 | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2020-09-10 | — | — | US | disclosed |
| US-20190382763-A1 | Compositions and Methods for Inhibition of Factor XII Gene Expression | Arrowhead Pharmaceuticals, Inc. | 2019-12-19 | — | — | US | disclosed |
| US-20190078089-A1 | RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10995335-B2 | RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use | TEK, PLIN3, PNLIP | GLP1R 459/4885TLR2 3137/4885 |
| US-11492624-B2 | RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1 | ASGR1, LDLR, SCARB1 | GLP1R 217/4885TLR2 712/4885 |
| US-20200283777-A1 | RNAi Agents And Compositions for Inhibiting Expression of Asiaglycoprotein Receptor 1 | ASGR1, LDLR, SCARB1 | GLP1R 405/4885TLR2 1013/4885 |
| US-20190078089-A1 | RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use | TEK, PLIN3, PNLIP | GLP1R 459/4885TLR2 3137/4885 |
| US-20190382763-A1 | Compositions and Methods for Inhibition of Factor XII Gene Expression | F12, F13A1, F13B | GLP1R 4018/4885TLR2 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.